300534.SHE Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
- Market cap
- CNY 2.99B
- P/E
- 123.4x
- P/B
- 4.12x
- ROE
- 0.6%
- Dividend yield
- 0.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300534.SHE undervalued?
Graham numberThe Graham number of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd fundamental analysis
No fundamental analysis for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd yet.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002 and is based in Lanzhou, China.
Full company profileGansu Longshenrongfa Pharmaceutical Industry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 270M | 270M | 203M | 239M | 255M | 288M | 800M | 1.08B | 1.04B | 887M | 607M |
| Gross Profit | 97.7M | 87.8M | 85.7M | 90.4M | 82.9M | 92.3M | 458M | 693M | 751M | 606M | 387M |
| Operating Income | 50.1M | 18.1M | 13.5M | 19.5M | 2.25M | -9.38M | 62.3M | 95.2M | 106M | 106M | 46.3M |
| EBITDA | 61.6M | 34.4M | 31.7M | 40.6M | 25.4M | 18.4M | 93.2M | 131M | 144M | 128M | 44.1M |
| Net Income | 47.3M | 17.1M | 12.3M | 12.8M | 1.83M | -9.11M | 38.8M | 61.6M | 25.8M | 44.0M | 3.97M |
| EPS | 0.19 | 0.06 | 0.04 | 0.04 | 0.01 | -0.03 | 0.13 | 0.20 | 0.09 | 0.14 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 763M | 782M | 779M | 810M | 867M | 824M | 913M | 1.34B | 1.40B | 1.39B | 1.31B |
| Total Liabilities | 59.7M | 70.0M | 57.7M | 71.3M | 128M | 91.2M | 150M | 625M | 674M | 613M | 522M |
| Shareholders' Equity | 704M | 712M | 721M | 731M | 729M | 720M | 746M | 634M | 662M | 708M | 705M |
| Cash & Short-term Investments | 124M | 58.6M | 63.0M | 51.6M | 118M | 99.1M | 97.8M | 289M | 290M | 241M | 211M |
| Total Debt | 2.19M | 10.0M | 10.0M | 24.0M | 70.1M | - | - | 143M | 98.4M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 13.1M | -2.05M | 10.2M | 28.2M | 43.5M | 51.1M | 11.4M | 96.5M | 170M | -6.54M | - |
| Capital Expenditure | 53.0M | 55.7M | 2.78M | 28.5M | 18.6M | 414K | 13.6M | 126M | 78.2M | 43.4M | 32.7M |
| Free Cash Flow | -39.9M | -57.8M | 7.46M | -315K | 24.9M | 50.7M | -2.20M | -29.8M | 91.9M | -49.9M | -8.45M |
| Ratios | |||||||||||
| ROE | 6.7% | 2.4% | 1.7% | 1.7% | 0.3% | -1.3% | 5.2% | 9.7% | 3.9% | 6.2% | 0.6% |
| ROA | 6.2% | 2.2% | 1.6% | 1.6% | 0.2% | -1.1% | 4.2% | 4.6% | 1.8% | 3.2% | 0.3% |
| Net Profit Margin | 17.5% | 6.3% | 6.0% | 5.3% | 0.7% | -3.2% | 4.9% | 5.7% | 2.5% | 5.0% | 0.7% |
| Debt to Equity | 0.00x | 0.01x | 0.01x | 0.03x | 0.10x | - | - | 0.23x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd dividends
- Dividend yield
- 0.50%
- Forward dividend
- 0.04 CNY
- Payout ratio
- 33.7%
- Ex-dividend date
- May 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 14.8M | 0.05 | 33.7% |
| 2024 | CNY 15.3M | 0.05 | 59.3% |
| 2023 | CNY 3.82M | 0.01 | 6.2% |
| 2022 | CNY 495K | 0.00 | 1.3% |
| 2021 | CNY 535K | 0.00 | - |
| 2020 | CNY 3.03M | 0.01 | 165.7% |
| 2019 | CNY 3.03M | 0.01 | 23.7% |
| 2018 | CNY 4.03M | 0.01 | 32.8% |
| 2017 | CNY 8.67M | 0.03 | 50.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 35:10 on May 10, 2017.
Who owns Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
- Insiders 40.22%
- Institutions 2.26%
- Public & others 57.52%
- Shares outstanding 303M
- Free float 187M
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd company profile
- Company name
- Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
- Ticker
- 300534.SHE
- ISIN
- CNE100002CP5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 641
- Fiscal year end
- December
- Address
- No. 138, Jinke Road, Lanzhou, China, 730102
- Phone
- 86 93 1214 3336
- Website
- lsrfzy.com
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002 and is based in Lanzhou, China.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd management
5- Ms. Yue Hong SongGM, Chief Engineer & Director · born 1974
- Ms. Rong XiaoChief Financial Officer · born 1985
- Mr. Qin Hui YuanDeputy GM, Secretary of the Board & Director · born 1975
- Mr. Bo SunDeputy General Manager · born 1986
- Mr. Wen Liang ChenDeputy General Manager · born 1984